Form 4: Nektar R&D Chief Sells Shares Under 10b5-1 Plan

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 485 shares of common stock for a weighted average price of $30.1 per share pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported a sale of common stock.
• The transaction involved 485 shares of Nektar Therapeutics common stock.
• The shares were sold on September 2, 2025, at a weighted average price of $30.1 per share.
• The sale was executed under a Rule 10b5-1 trading plan, which was adopted by the reporting person.
• Following this transaction, Mr. Zalevsky beneficially owns 19,183 shares of common stock.

Sentiment

Score: 5

Explanation: The sale of shares by an insider, even under a 10b5-1 plan, is generally viewed as neutral to slightly negative. The small number of shares sold relative to total holdings and the pre-arranged nature of the sale mitigate significant negative sentiment.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on immediate material non-public information, which enhances corporate governance transparency.

Negatives

• The Chief R&D Officer reduced his direct beneficial ownership by 485 shares.

Industry Context

This filing is a standard insider transaction report and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, potentially viewed neutrally given the 10b5-1 plan.

Key Dates

Keywords

Nektar Therapeutics, NKTR, Jonathan Zalevsky, Insider Sale, Form 4, 10b5-1 Plan, Chief R&D Officer, Stock Transaction